IFP Advisors’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $35 | Buy |
+9
| New | +$35 | ﹤0.01% | 5091 |
|
|
2024
Q1 | – | Sell |
-2,000
| Closed | -$3.32K | – | 3161 |
|
|
2023
Q4 | $3.32K | Hold |
2,000
| – | – | ﹤0.01% | 2545 |
|
|
2023
Q3 | $3.84K | Hold |
2,000
| – | – | ﹤0.01% | 2609 |
|
|
2023
Q2 | $2.88K | Hold |
2,000
| – | – | ﹤0.01% | 2756 |
|
|
2023
Q1 | $9.8K | Sell |
2,000
-1,000
| -33% | -$1.62K | ﹤0.01% | 2293 |
|
|
2022
Q4 | $14K | Buy |
3,000
+300
| +11% | +$400 | ﹤0.01% | 3146 |
|
|
2022
Q3 | $13K | Buy |
2,700
+200
| +8% | +$374 | ﹤0.01% | 3439 |
|
|
2022
Q2 | $12K | Hold |
2,500
| – | – | ﹤0.01% | 3249 |
|
|
2022
Q1 | $12K | Hold |
2,500
| – | – | ﹤0.01% | 3247 |
|
|
2021
Q4 | $5K | Hold |
2,500
| – | – | ﹤0.01% | 2485 |
|
|
2021
Q3 | $10K | Buy |
2,500
+2,000
| +400% | +$6.78K | ﹤0.01% | 2267 |
|
|
2021
Q2 | $2K | Hold |
500
| – | – | ﹤0.01% | 2740 |
|
|
2021
Q1 | $1K | Hold |
500
| – | – | ﹤0.01% | 2819 |
|
|
2020
Q4 | $1K | Hold |
500
| – | – | ﹤0.01% | 2754 |
|
|
2020
Q3 | $1K | Hold |
500
| – | – | ﹤0.01% | 2630 |
|
|
2020
Q2 | $2K | Hold |
500
| – | – | ﹤0.01% | 2387 |
|
|
2020
Q1 | $1K | Hold |
500
| – | – | ﹤0.01% | 2531 |
|
|
2019
Q4 | $1K | Hold |
500
| – | – | ﹤0.01% | 2665 |
|
|
2019
Q3 | $2K | Buy |
+500
| New | +$1.81K | ﹤0.01% | 2688 |
|
|
2019
Q1 | $21K | Sell |
4,200
-3,600
| -46% | -$17.3K | ﹤0.01% | 1324 |
|
|
2018
Q4 | $29K | Sell |
7,800
-454
| -6% | -$2.17K | ﹤0.01% | 1917 |
|
|
2018
Q3 | $50K | Buy |
8,254
+2,954
| +56% | +$16.3K | ﹤0.01% | 1895 |
|
|
2018
Q2 | $34K | Buy |
5,300
+100
| +2% | +$487 | ﹤0.01% | 2138 |
|
|
2018
Q1 | $17K | Hold |
5,200
| – | – | ﹤0.01% | 2488 |
|
|
2017
Q4 | $17K | Sell |
5,200
-800
| -13% | -$2.02K | ﹤0.01% | 2524 |
|
|
2017
Q3 | $13K | Hold |
6,000
| – | – | ﹤0.01% | 2875 |
|
|
2017
Q2 | $15K | Hold |
6,000
| – | – | ﹤0.01% | 2748 |
|
|
2017
Q1 | $14K | Hold |
6,000
| – | – | ﹤0.01% | 2716 |
|
|
2016
Q4 | $6K | Sell |
6,000
-1,000
| -14% | -$889 | ﹤0.01% | 3188 |
|
|
2016
Q3 | $8K | Buy |
7,000
+300
| +4% | +$533 | ﹤0.01% | 2967 |
|
|
2016
Q2 | $10K | Buy |
6,700
+2,500
| +60% | +$3.67K | ﹤0.01% | 2740 |
|
|
2016
Q1 | $21K | Sell |
4,200
-3,250
| -44% | -$4.36K | ﹤0.01% | 1327 |
|
|
2015
Q4 | $12K | Buy |
+7,450
| New | +$17.1K | ﹤0.01% | 2474 |
|
Other funds holding GALT
IFP Advisors's GALT Position: Q3 2026 in Review
IFP Advisors opened a new position in Galectin Therapeutics (GALT) in Q3 2026: 9 shares worth $35. The stake represents ﹤0.01% of the portfolio and ranks #5091 among its holdings. This is a return to the name: IFP Advisors previously reported a position in GALT as recently as Q4 2023.
IFP Advisors first reported a position in GALT in Q4 2015 and has held it in 33 quarters since. The position peaked at $50K in Q3 2018. 32 funds tracked by Wall St. Rank hold GALT as of Q3 2026.
- IFP Advisors held 9 shares of Galectin Therapeutics worth $35 as of Q3 2026.
- Galectin Therapeutics was a new IFP Advisors position in Q3 2026.
- Galectin Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #5091 holding.
- IFP Advisors first reported a position in Galectin Therapeutics in Q4 2015 and has held it in 33 quarters since.
- IFP Advisors's Galectin Therapeutics position peaked at $50K in Q3 2018.
- 32 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2026.
Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.